Patients with T2D often exhibit a state of chronic low-grade systemic inflammation characterized by a marked increase in circulating levels of acute-phase proteins and proinflammatory chemokines, cytokines, and adipokines—including C-reactive protein (CRP), tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, visfatin, and resistin—accompanied by a decrease in anti-inflammatory and insulin-sensitizing adipokines such as adiponectin and omentin [8,9,10,11,12,13,14]. This evidence concerns the gene IL1A and type 2 diabetes mellitus.